Videos

Nancy Lurker, CEO of EyePoint Pharmaceuticals, shares the 12-month safety data from the DAVIO trial, investigating EYP-1901 for the treatment of wet age-related macular degeneration (AMD) and nonproliferative diabetic retinopathy.

DAVIO trial update: 12-month safety results indicate no serious adverse events, reduced treatment burden

A retina specialist discusses impressions and key takeaway points from the case of an 81-year-old female with treatment experienced nAMD. 

Impressions and Takeaway Points From nAMD Patient Case #2

David A. Eichenbaum, MD, FASRS, reviews the case of a 81-year-old female with treatment experienced neovascular age-related macular degeneration (nAMD).

Patient Case #2: 81-Year-Old Male With nAMD

A retina specialist discusses impressions and key takeaway points from the case of a 74-year-old male with DME.

Impressions and Takeaway Points From DME Patient Case #1

David A. Eichenbaum, MD, FASRS, reviews the case of a 74-year-old male with diabetic macular edema (DME). 

Patient Case #1: 74-Year-Old Male With DME

Articles

Kodiak Sciences Inc. announced that its BEACON Phase 3 study of tarcocimab, its novel antibody biopolymer conjugate, met the primary endpoint of non-inferior change from baseline in visual acuity at week 24 compared to aflibercept in patients with macular edema due to retinal vein occlusion.

Phase 3 BEACON study delivers positive topline results for tarcocimab in patients with retinal vein occlusion

Victor Gonzalez, MD, shares updates from the Phase 4 Paladin study regarding the safety and efficacy of fluocinolone in diabetic macular edema.

Phase 4 Paladin finds fluocinolone to be safe, effective in patients with diabetic macular edema

The U.S. Food and Drug Administration has approved Coherus’ ranibizumab-eqrn (Cimerli) as an interchangeable biosimilar for all five indications of Lucentis.

FDA approves interchangeable ranibizumab biosimilar from Coherus BioSciences

An end-of-week review of retina news and stories from August 6-August 12.

This week in retina: August 6-August 12

Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of 

This year’s hybrid meeting will allow attendees to participate in person or virtually. Either way, this congress will offer a wealth of information to specialists covering all aspects of retinal diseases.

FDA approves interchangeable ranibizumab biosimilar from Coherus BioSciences

This week in retina: August 6-August 12

EURETINA 2022: Stepping into the future of ophthalmology